FDA delays action on Alzheimer's drug from Lilly
The Food and Drug Administration (FDA) is delaying approval of a new Alzheimer’s drug from Eli Lilly, and it instead will require the company to face an advisory panel to scrutinize its safety and effectiveness data, the company said Friday. “The FDA has informed Lilly it wants to further understand topics related to evaluating the […]